Trial Profile

A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects with Recurrent And/or Metastatic HNSCC and High-Risk HPV16 Infection

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PDS 0101 (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms VERSATILE-002
Sponsors PDS Biotechnology Corporation

Most Recent Events

02 Jun 2025 According to a PDS Biotechnology Corporation Media Release, the data from this study were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
02 Jun 2025 Results presented in the PDS Biotechnology Corporation Media Release.
22 May 2025 Results (n=53) presented in the Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com